Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 to 29 (Cancelled).

30. (New) An Ig fraction obtained by a method comprising the following steps:

a) preparing an insoluble support onto which is grafted a component selected from the group consisting of polyvalent IgGs, polyvalent IgMs and DNP-lysin,

b) adsorbing polyvalent Igs onto the support obtained in step a),

c) eluting the Igs retained on the portion of immunoglobulins bound to the support, so as to collect the fraction connected through IgG-IgG or IgM-IgG idiotypic interactions, or eluting the fraction which interacts with DNP,

d) selecting the fractions having reactivity with respect to IgMs, IgG F(ab')2s or the hapten DNP, little or no reactivity with respect to non-self antigens and/or polyreactivity with respect to autoantigens, and

e) selecting the fractions having activity which inhibits the proliferation of lymphocytes in mixed culture.

31. (New) The Ig fraction of claim 30, wherein the selected fraction inhibits the proliferation of lymphocytes 10 to 50 times more effectively than commercially available, polyvalent IgGs.

32. (New) The Ig fraction of claim 30, wherein the Ig fraction contains Igs selected from the group consisting of IgGs and IgMs.

33. (New) A method for preparing the Ig fraction of claim 30, wherein the Ig fractions are prepared from polyvalent Igs.

34. (New) The method of claim 33, wherein the polyvalent Igs used to prepare the fractions consist of IgGs or IgMs.

35. (New) A method for preparing the Ig fraction of claim 30, wherein step d) further comprises measuring the level of enrichment of antibodies reactive against IgMs, IgG F(ab')2s or the hapten DNP used for the purification.

36. (New) A method for preparing the Ig fraction of claim 30, wherein step d) comprises an ELISA carried out on a panel of autoantigens selected from the group consisting of actin, myosin, MBP and tubulin.

37. (New) A method for preparing the Ig fraction of claim 30, wherein the Igs retained in step b) are eluted with a buffer comprising a chaotrope selected from the group consisting of glycine-HCl and sodium iodide.

38. (New) A method for preparing the Ig fraction of claim 30, wherein the adsorption step is carried out under temperature conditions ranging from 4° to 40°C and in phosphate buffered saline.

39. (New) A method of treating an autoimmune disease in a patient comprising administering to said patient an effective amount of the composition of claim 30.

40. (New) A method of treating graft-versus-host-disease in a patient comprising administering to said patient an effective amount of the composition of claim 30.

41. (New) A method of preventing or treating graft rejection after transplantation in a patient comprising administering to said patient an effective amount of the composition of claim 30.

42. (New) A method of treating a neurological disease in a patient comprising administering to said patient an effective amount of the composition of claim 30.

43. (New) The method of claim 42, wherein the neurological disease is selected from the group consisting of adult Guillain-Barre syndrome, chronic demyelinating inflammatory polyneuropathies, dermatomyositis, myasthenia and multiple sclerosis.